{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:53:19Z","timestamp":1787169199216,"version":"build-2736575974"},"reference-count":99,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017547","name":"Spark Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017547","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jtha.2023.06.016","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T17:42:48Z","timestamp":1687369368000},"page":"2354-2361","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Hemophilia gene therapy: first, do no harm"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0685-3752","authenticated-orcid":false,"given":"Leonard A.","family":"Valentino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8084-1958","authenticated-orcid":false,"given":"Radoslaw","family":"Kaczmarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3310-328X","authenticated-orcid":false,"given":"Glenn F.","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2183-4277","authenticated-orcid":false,"given":"Declan","family":"Noone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9780-6972","authenticated-orcid":false,"given":"Brian","family":"O\u2019Mahony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5009-260X","authenticated-orcid":false,"given":"David","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3354-3880","authenticated-orcid":false,"given":"Dawn","family":"Rotellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0934-0680","authenticated-orcid":false,"given":"Mark W.","family":"Skinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2023.06.016_bib1","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","article-title":"The hemophilias\u2014from royal genes to gene therapy","volume":"344","author":"Mannucci","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.06.016_bib2","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1111\/hae.13504","article-title":"Core outcome set for gene therapy in haemophilia: results of the coreHEM multistakeholder project","volume":"24","author":"Iorio","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.06.016_bib3","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1111\/jth.15023","article-title":"ISTH subcommittee on Factor VIII, Factor IX, rare bleeding disorders. Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: communication from the SSC of the ISTH","volume":"18","author":"Konkle","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.06.016_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30264","article-title":"Cost-effectiveness analysis of recombinant factor IX Fc fusion protein compared with recombinant factor IX for the treatment of moderate-severe to severe hemophilia B in China","volume":"70","author":"Zhou","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtha.2023.06.016_bib5","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/17474086.2020.1716726","article-title":"The cost of hemophilia treatment: the importance of minimizing it without detriment to its quality","volume":"13","author":"Rodriguez-Merchan","year":"2020","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.jtha.2023.06.016_bib6","first-page":"363","article-title":"Adult lifetime cost of hemophilia B management in the US: payer and societal perspectives from a decision analytic model","volume":"24","author":"Li","year":"2021","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.jtha.2023.06.016_bib7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14737167.2020.1789457","article-title":"Cost of patients with hemophilia A treated with standard half-life or extended half-life FVIII in Spain","volume":"21","author":"Kim","year":"2021","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.jtha.2023.06.016_bib8","first-page":"316","article-title":"Health care resource utilization and costs among adult patients with hemophilia A on factor VIII prophylaxis: an administrative claims analysis","volume":"27","author":"Croteau","year":"2021","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.jtha.2023.06.016_bib9","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2147\/PPA.S202773","article-title":"Real-world utilities and health-related quality-of-life data in hemophilia patients in France and the United Kingdom","volume":"13","author":"Carroll","year":"2019","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jtha.2023.06.016_bib10","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/bloodadvances.2020003424","article-title":"Health care resource utilization and cost burden of hemophilia B in the United States","volume":"5","author":"Buckner","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2023.06.016_bib11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s41687-023-00550-6","article-title":"Understanding treatment burden in hemophilia: development and validation of the Hemophilia Treatment Experience Measure (Hemo-TEM)","volume":"7","author":"Brod","year":"2023","journal-title":"J\u00a0Patient Rep Outcomes"},{"key":"10.1016\/j.jtha.2023.06.016_bib12","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jval.2017.04.017","article-title":"Economic burden of illness among persons with hemophilia B from HUGS Vb: examining the association of severity and treatment regimens with costs and annual bleed rates","volume":"20","author":"Chen","year":"2017","journal-title":"Value Health"},{"key":"10.1016\/j.jtha.2023.06.016_bib13","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/hae.14363","article-title":"The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies","volume":"27","author":"Skinner","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.06.016_bib14","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2209226","article-title":"Efanesoctocog alfa prophylaxis for patients with severe hemophilia A","volume":"388","author":"von Drygalski","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.06.016_bib15","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2015-10-675140","article-title":"Men with severe hemophilia in the United States: birth cohort analysis of a large national database","volume":"127","author":"Mazepa","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.06.016_bib16","first-page":"897","article-title":"Integrated hemophilia patient care via a national network of care centers in the United States: a model for rare coagulation disorders","volume":"12","author":"Valentino","year":"2021","journal-title":"J\u00a0Blood Med"},{"key":"10.1016\/j.jtha.2023.06.016_bib17","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jtha.2022.12.029","article-title":"Hemophilia treatment innovation: 50 years of progress and more to come","volume":"21","author":"Mannucci","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.06.016_bib18","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1182\/blood-2006-10-050435","article-title":"Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV","volume":"110","author":"Darby","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.06.016_bib19","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/jth.15182","article-title":"Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001-2018","volume":"19","author":"Hassan","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.06.016_bib20","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1538-7836.2006.01776.x","article-title":"Life expectancy in hemophilia outcome","volume":"4","author":"Mejia-Carvajal","year":"2006","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.06.016_bib21","first-page":"229","article-title":"Comorbidities, health-related quality of life, health-care utilization in older persons with hemophilia-Hematology Utilization Group Study Part VII (HUGS VII)","volume":"13","author":"Curtis","year":"2022","journal-title":"J\u00a0Blood Med"},{"key":"10.1016\/j.jtha.2023.06.016_bib22","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/rth2.12202","article-title":"Impact of prophylaxis on health-related quality of life of boys with hemophilia: an analysis of pooled data from 9 countries","volume":"3","author":"Usuba","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.06.016_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12627","article-title":"Social participation and hemophilia: self-perception, social support, and their influence on boys in Canada","volume":"5","author":"Chiu","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.06.016_bib24","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1182\/blood-2007-07-102202","article-title":"Social participation of patients with hemophilia in the Netherlands","volume":"111","author":"Plug","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.06.016_bib25","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1542\/peds.2009-0072","article-title":"Athletic participation in severe hemophilia: bleeding and joint outcomes in children on prophylaxis","volume":"124","author":"Ross","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.jtha.2023.06.016_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12741","article-title":"Socioeconomic participation of persons with hemophilia: results from the sixth hemophilia in the Netherlands study","volume":"6","author":"van Balen","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"Suppl 1","key":"10.1016\/j.jtha.2023.06.016_bib27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/hae.14105","article-title":"Non-severe haemophilia: is it benign? - Insights from the PROBE study","volume":"27","author":"Chai-Adisaksopha","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.06.016_bib28","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/hae.13703","article-title":"Exploring regional variations in the cross-cultural, international implementation of the Patient Reported Outcomes Burdens and Experience (PROBE) study","volume":"25","author":"Chai-Adisaksopha","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.06.016_bib29","doi-asserted-by":"crossref","first-page":"e689","DOI":"10.1016\/S2352-3026(22)00209-5","article-title":"Achieving access to haemophilia care in low-income and lower-middle-income countries: expanded Humanitarian Aid Program of the World Federation of Hemophilia after 5 years","volume":"9","author":"Pierce","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2023.06.016_bib30","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1001\/archinte.1976.03630070040012","article-title":"Comprehensive health care clinic for hemophiliacs","volume":"136","author":"Levine","year":"1976","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jtha.2023.06.016_bib31","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1749-6632.1975.tb53352.x","article-title":"A\u00a0boarding school for hemophiliacs: a model for the comprehensive care of hemophilic children","volume":"240","author":"Allain","year":"1975","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jtha.2023.06.016_bib32","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1542\/peds.51.6.986","article-title":"Delivery of care to hemophilic children: home care versus hospitalization","volume":"51","author":"Strawczynski","year":"1973","journal-title":"Pediatrics"},{"key":"10.1016\/j.jtha.2023.06.016_bib33","first-page":"263","article-title":"Comprehensive care for haemophilia","volume":"5","author":"Kerr","year":"1971","journal-title":"J\u00a0R Coll Physicians Lond"},{"key":"10.1016\/j.jtha.2023.06.016_bib34","first-page":"3","article-title":"[3 years of activity (1968-70) of a center for the care of hemophiliacs]","volume":"56","author":"Dioguardi","year":"1971","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2023.06.016_bib35","first-page":"111","article-title":"Our experience in Sweden with prophylaxis on haemophilia","volume":"34","author":"Nilsson","year":"1970","journal-title":"Bibl Haematol"},{"issue":"Suppl 86","key":"10.1016\/j.jtha.2023.06.016_bib36","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/ejh.12854","article-title":"Management of US men, women, and children with hemophilia and methods and demographics of the Bridging Hemophilia B Experiences, Results and Opportunities into Solutions (B-HERO-S) study","volume":"98","author":"Buckner","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtha.2023.06.016_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12825","article-title":"Burden of congenital hemophilia A requiring treatment in Japan: the HIKOBOSHI study","volume":"6","author":"Nagao","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.06.016_bib38","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.2147\/PPA.S139851","article-title":"Treatment adherence in hemophilia","volume":"11","author":"Thornburg","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jtha.2023.06.016_bib39","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.2147\/PPA.S212723","article-title":"Interrelationship between depression, anxiety, pain, and treatment adherence in hemophilia: results from a US cross-sectional survey","volume":"13","author":"Witkop","year":"2019","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jtha.2023.06.016_bib40","first-page":"337","article-title":"Theodore E. Woodward Award. AAV-mediated gene transfer for hemophilia","volume":"114","author":"High","year":"2003","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"10.1016\/j.jtha.2023.06.016_bib41","first-page":"517","article-title":"AAV-mediated gene therapy for hemophilia","volume":"5","author":"Couto","year":"2003","journal-title":"Curr Opin Mol Ther"},{"key":"10.1016\/j.jtha.2023.06.016_bib42","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/j.1538-7836.2007.02410.x","article-title":"Gene therapy, bioengineered clotting factors and novel technologies for hemophilia treatment","volume":"5","author":"Pierce","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.06.016_bib43","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1038\/mt.2011.203","article-title":"Cell phones and landlines: the impact of gene therapy on the cost and availability of treatment for hemophilia","volume":"19","author":"High","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.06.016_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/mt.2012.272","article-title":"Gene therapy for hemophilia: addressing the coming challenges of affordability and accessibility","volume":"21","author":"Skinner","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.06.016_bib45","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1016\/j.ymthe.2022.09.020","article-title":"First conditional marketing authorization approval in the European Union for hemophilia \u201cA\u201d gene therapy","volume":"30","author":"VandenDriessche","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.06.016_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymthe.2022.12.001","article-title":"First hemophilia B gene therapy approved: more than two decades in the making","volume":"31","author":"Herzog","year":"2023","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.06.016_bib47","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev-med-043021-033013","article-title":"Adeno-associated virus gene therapy for hemophilia","volume":"74","author":"Samelson-Jones","year":"2023","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jtha.2023.06.016_bib48","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/hae.14391","article-title":"Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A","volume":"27","author":"Pasi","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.06.016_bib49","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A","volume":"382","author":"Pasi","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.06.016_bib50","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-factor VIII gene transfer in severe hemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.06.016_bib51","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa2211075","article-title":"Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A","volume":"388","author":"Mahlangu","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.06.016_bib52","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.06.016_bib53","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2017-09-804419","article-title":"Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B","volume":"131","author":"Miesbach","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.06.016_bib54","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2020-139225","article-title":"AMT-060 gene therapy in adults with severe or moderate-severe hemophilia B confirm stable FIX expression and durable reductions in bleeding and factor IX consumption for up to 5 years","volume":"136","author":"Leebeek","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.06.016_bib55","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/bloodadvances.2019000811","article-title":"Etranacogene dezaparvovec (AMT-061 phase 2b): normal\/near normal FIX activity and bleed cessation in hemophilia B","volume":"3","author":"Von Drygalski","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2023.06.016_bib56","author":"Schmidt"},{"key":"10.1016\/j.jtha.2023.06.016_bib57","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.06.016_bib58","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.ymthe.2023.03.001","article-title":"Two gene therapies for hemophilia available: now what?","volume":"31","author":"Pierce","year":"2023","journal-title":"Mol Ther"},{"issue":"Suppl 3","key":"10.1016\/j.jtha.2023.06.016_bib59","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/hae.14023","article-title":"Uncertainty in an era of transformative therapy for haemophilia: addressing the unknowns","volume":"27","author":"Pierce","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.06.016_bib60","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1177\/2168479018791560","article-title":"Managing the risks of medicines: an examination of FDA\u2019s application of criteria for requiring a REMS","volume":"53","author":"Seligman","year":"2019","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.jtha.2023.06.016_bib61","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fpubh.2020.00043","article-title":"Adaptation for regulatory application: a content analysis of FDA risk evaluation and mitigation strategies assessment plans (2014-2018) using RE-AIM","volume":"8","author":"Toyserkani","year":"2020","journal-title":"Front Public Health"},{"key":"10.1016\/j.jtha.2023.06.016_bib62","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1080\/14740338.2021.1909569","article-title":"Regulatory experience of handling risk management plans (RMPs) for medicinal products in the EU","volume":"20","author":"Butler","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jtha.2023.06.016_bib64","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s40265-019-01162-5","article-title":"Onasemnogene abeparvovec: first global approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.jtha.2023.06.016_bib65","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221145627","article-title":"How to translate and implement the current science of gene therapy into haemophilia care?","volume":"14","author":"Hermans","year":"2023","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.jtha.2023.06.016_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100759","article-title":"Discussing investigational AAV gene therapy with hemophilia patients: a guide","volume":"47","author":"Sidonio","year":"2021","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtha.2023.06.016_bib67","doi-asserted-by":"crossref","first-page":"69","DOI":"10.17225\/jhp00178","article-title":"Personalising haemophilia management with shared decision making","volume":"8","author":"Valentino","year":"2021","journal-title":"J\u00a0Haem Pract"},{"key":"10.1016\/j.jtha.2023.06.016_bib68","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood.2019004625","article-title":"BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression","volume":"137","author":"Konkle","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.06.016_bib69","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1182\/blood-2022-164440","article-title":"Vector analysis of multicentric lymphoma in a severe hemophilia A dog after AAV gene therapy","volume":"140","author":"Van Gorder","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.06.016_bib70","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/rth2.12195","article-title":"Hemophilia trials in the twenty-first century: defining patient important outcomes","volume":"3","author":"Konkle","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.06.016_bib71","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12488","article-title":"Patient-relevant health outcomes for hemophilia care: development of an international standard outcomes set","volume":"5","author":"van Balen","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.06.016_bib72","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/hae.14015","article-title":"Members of the WFH Gene Therapy Registery Steering Committee. World Federation of Hemophilia Gene Therapy Registry","volume":"26","author":"Konkle","year":"2020","journal-title":"Haemophilia"},{"issue":"Suppl 3","key":"10.1016\/j.jtha.2023.06.016_bib73","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/hae.13972","article-title":"The critical need for postmarketing surveillance in gene therapy for haemophilia","volume":"27","author":"Konkle","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.06.016_bib74","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2516.2010.02450.x","article-title":"Trends in bleeding patterns during prophylaxis for severe haemophilia: observations from a series of prospective clinical trials","volume":"17","author":"Fischer","year":"2011","journal-title":"Haemophilia"},{"issue":"Suppl 4","key":"10.1016\/j.jtha.2023.06.016_bib75","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2516.2012.02838.x","article-title":"Personalized prophylaxis","volume":"18","author":"Collins","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.06.016_bib76","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1055\/s-0040-1709519","article-title":"Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia A initiated on tertiary prophylaxis","volume":"120","author":"Chowdary","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.06.016_bib77","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1111\/hae.14546","article-title":"Gene therapy of hemophilia: hub centres should be haemophilia centres: a joint publication of EAHAD and EHC","volume":"28","author":"Miesbach","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.06.016_bib78","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/hae.14309","article-title":"Evolution of haemophilia integrated care in the era of gene therapy: treatment centre\u2019s readiness in United States and EU","volume":"27","author":"Miesbach","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.06.016_bib79","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/hae.14420","article-title":"Delivery of AAV-based gene therapy through haemophilia centres-A need for re-evaluation of infrastructure and comprehensive care: A Joint publication of EAHAD and EHC","volume":"27","author":"Miesbach","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.06.016_bib80","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1016\/j.ymthe.2021.10.025","article-title":"Eliminating Panglossian thinking in development of AAV therapeutics","volume":"29","author":"Kaczmarek","year":"2021","journal-title":"Mol Ther"},{"issue":"Suppl 3","key":"10.1016\/j.jtha.2023.06.016_bib81","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/hae.14027","article-title":"Delivering on the promise of gene therapy for haemophilia","volume":"27","author":"Pipe","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.06.016_bib82","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2104205","article-title":"Multiyear factor VIII expression after AAV gene transfer for hemophilia A","volume":"385","author":"George","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.06.016_bib83","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.ymthe.2022.03.004","article-title":"Durability of transgene expression after rAAV gene therapy","volume":"30","author":"Muhuri","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.06.016_bib84","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.06.016_bib85","doi-asserted-by":"crossref","unstructured":"von Drygalski A, Gomez E, Giermasz A, Castaman G, Key NS, Lattimore SS, Leebeek FWG, Miesbach WA, Recht M, Gut RZ, Dolmetsch R, Monahan PE, Le Quellec S, Pipe SW. Stable and durable factor IX levels in hemophilia B patients over 3 years post etranacogene dezaparvovec gene therapy. Blood Adv. Published online December 9, 2022. https:\/\/doi.org\/10.1182\/bloodadvances.2022008886","DOI":"10.1182\/bloodadvances.2022008886"},{"key":"10.1016\/j.jtha.2023.06.016_bib86","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/03007995.2022.2133492","article-title":"Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B","volume":"39","author":"Shah","year":"2023","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jtha.2023.06.016_bib87","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/hae.13862","article-title":"Achieving the unimaginable: health equity in haemophilia","volume":"26","author":"Skinner","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.06.016_bib88","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/hae.14012","article-title":"The World Federation of Hemophilia Annual Global Survey 1999-2018","volume":"26","author":"Stonebraker","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.06.016_bib89","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7326\/M19-1208","article-title":"Data and Demographics Committee of the World Federation of Hemophilia. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries","volume":"171","author":"Iorio","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2023.06.016_bib90","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ajmg.c.32032","article-title":"Gene-targeted therapies: towards equitable development, diagnosis, and access","volume":"193","author":"Gaviglio","year":"2023","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"10.1016\/j.jtha.2023.06.016_bib91","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jtha.2022.12.027","article-title":"The ethics of gene therapy for hemophilia: a narrative review","volume":"21","author":"Baas","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.06.016_bib92","author":"Clearfield"},{"key":"10.1016\/j.jtha.2023.06.016_bib93","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12567","article-title":"Living with a \u201chemophilia-free mind\u201d\u2014the new ambition of hemophilia care?","volume":"5","author":"Krumb","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.06.016_bib94","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1056\/NEJMp1109283","article-title":"Shared decision making--pinnacle of patient-centered care","volume":"366","author":"Barry","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.06.016_bib95","doi-asserted-by":"crossref","first-page":"c5146","DOI":"10.1136\/bmj.c5146","article-title":"Implementing shared decision making in the NHS","volume":"341","author":"Elwyn","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.jtha.2023.06.016_bib96","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/2040620718784830","article-title":"The role of patient and healthcare professionals in the era of new hemophilia treatments in developed and developing countries","volume":"9","author":"Nossair","year":"2018","journal-title":"Ther Adv Hematol"},{"issue":"Suppl 4","key":"10.1016\/j.jtha.2023.06.016_bib97","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/hae.14545","article-title":"Gene therapy: practical aspects of implementation","volume":"28","author":"Pipe","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.06.016_bib98","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s13023-020-01555-w","article-title":"Optimizing language for effective communication of gene therapy concepts with hemophilia patients: a qualitative study","volume":"16","author":"Hart","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jtha.2023.06.016_bib99","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/rth2.12326","article-title":"Hemophilia gene therapy knowledge and perceptions: results of an international survey","volume":"4","author":"Peyvandi","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.06.016_bib100","doi-asserted-by":"crossref","DOI":"10.1177\/20420986221146418","article-title":"Patient-centered pharmacovigilance: priority actions from the inherited bleeding disorders community","volume":"14","author":"Robinson","year":"2023","journal-title":"Ther Adv Drug Saf"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623005019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623005019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:40:19Z","timestamp":1761536419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783623005019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":99,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1538783623005019"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2023.06.016","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hemophilia gene therapy: first, do no harm","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2023.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}